{"id":108423,"date":"2021-05-26T04:40:37","date_gmt":"2021-05-26T04:40:37","guid":{"rendered":"https:\/\/www.healthbenefitstimes.com\/glossary\/?p=108423"},"modified":"2021-05-26T04:40:37","modified_gmt":"2021-05-26T04:40:37","slug":"carnitine-palmitoyltransferase-deficiency-type-ii","status":"publish","type":"post","link":"https:\/\/www.healthbenefitstimes.com\/glossary\/carnitine-palmitoyltransferase-deficiency-type-ii\/","title":{"rendered":"Carnitine palmitoyltransferase deficiency, type II"},"content":{"rendered":"<p>Carnitine palmitoyltransferase deficiency (CPT) is a very rare autosomal recessive genetic disease created from the interaction of one gene from the mother and one gene from the father. Thus, the condition does not appear in the child unless the same defective gene for the same trait from each parent is inherited. If only one normal and one gene with the disease are passed on, the child will be a carrier of the disease but usually will not show symptoms. If both parents are carriers of the recessive disease, the child has a 25% chance of demonstrating positive symptoms of the disease, a 50% chance of being of carrier, and a 25% chance of receiving both normal genes from each parent.<\/p>\n<hr \/>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Carnitine palmitoyltransferase deficiency (CPT) is a very rare autosomal recessive genetic disease created from the interaction of one gene from the mother and one gene from the father. Thus, the condition does not appear in the child unless the same defective gene for the same trait from each parent is inherited. If only one normal [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-108423","post","type-post","status-publish","format-standard","hentry","category-c"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Carnitine palmitoyltransferase deficiency, type II - Definition of Carnitine palmitoyltransferase deficiency, type II<\/title>\n<meta name=\"description\" content=\"Carnitine palmitoyltransferase deficiency (CPT) is a very rare autosomal recessive genetic disease created from the interaction of one gene from the mother and one gene from the father. Thus, the condition does not appear in the child unless the same defective gene for the same trait from each parent is inherited. If only one normal and one gene with the disease are passed on, the child will be a carrier of the disease but usually will not show symptoms. If both parents are carriers of the recessive disease, the child has a 25% chance of demonstrating positive symptoms of the disease, a 50% chance of being of carrier, and a 25% chance of receiving both normal genes from each parent.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.healthbenefitstimes.com\/glossary\/carnitine-palmitoyltransferase-deficiency-type-ii\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Carnitine palmitoyltransferase deficiency, type II - Definition of Carnitine palmitoyltransferase deficiency, type II\" \/>\n<meta property=\"og:description\" content=\"Carnitine palmitoyltransferase deficiency (CPT) is a very rare autosomal recessive genetic disease created from the interaction of one gene from the mother and one gene from the father. Thus, the condition does not appear in the child unless the same defective gene for the same trait from each parent is inherited. If only one normal and one gene with the disease are passed on, the child will be a carrier of the disease but usually will not show symptoms. If both parents are carriers of the recessive disease, the child has a 25% chance of demonstrating positive symptoms of the disease, a 50% chance of being of carrier, and a 25% chance of receiving both normal genes from each parent.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.healthbenefitstimes.com\/glossary\/carnitine-palmitoyltransferase-deficiency-type-ii\/\" \/>\n<meta property=\"og:site_name\" content=\"Glossary\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-26T04:40:37+00:00\" \/>\n<meta name=\"author\" content=\"Glossary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Glossary\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/carnitine-palmitoyltransferase-deficiency-type-ii\/\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/carnitine-palmitoyltransferase-deficiency-type-ii\/\",\"name\":\"Carnitine palmitoyltransferase deficiency, type II - Definition of Carnitine palmitoyltransferase deficiency, type II\",\"isPartOf\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\"},\"datePublished\":\"2021-05-26T04:40:37+00:00\",\"dateModified\":\"2021-05-26T04:40:37+00:00\",\"author\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\"},\"description\":\"Carnitine palmitoyltransferase deficiency (CPT) is a very rare autosomal recessive genetic disease created from the interaction of one gene from the mother and one gene from the father. Thus, the condition does not appear in the child unless the same defective gene for the same trait from each parent is inherited. If only one normal and one gene with the disease are passed on, the child will be a carrier of the disease but usually will not show symptoms. If both parents are carriers of the recessive disease, the child has a 25% chance of demonstrating positive symptoms of the disease, a 50% chance of being of carrier, and a 25% chance of receiving both normal genes from each parent.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/carnitine-palmitoyltransferase-deficiency-type-ii\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.healthbenefitstimes.com\/glossary\/carnitine-palmitoyltransferase-deficiency-type-ii\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/carnitine-palmitoyltransferase-deficiency-type-ii\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Carnitine palmitoyltransferase deficiency, type II\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\",\"name\":\"Glossary\",\"description\":\"Difinitions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\",\"name\":\"Glossary\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Carnitine palmitoyltransferase deficiency, type II - Definition of Carnitine palmitoyltransferase deficiency, type II","description":"Carnitine palmitoyltransferase deficiency (CPT) is a very rare autosomal recessive genetic disease created from the interaction of one gene from the mother and one gene from the father. Thus, the condition does not appear in the child unless the same defective gene for the same trait from each parent is inherited. If only one normal and one gene with the disease are passed on, the child will be a carrier of the disease but usually will not show symptoms. If both parents are carriers of the recessive disease, the child has a 25% chance of demonstrating positive symptoms of the disease, a 50% chance of being of carrier, and a 25% chance of receiving both normal genes from each parent.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.healthbenefitstimes.com\/glossary\/carnitine-palmitoyltransferase-deficiency-type-ii\/","og_locale":"en_US","og_type":"article","og_title":"Carnitine palmitoyltransferase deficiency, type II - Definition of Carnitine palmitoyltransferase deficiency, type II","og_description":"Carnitine palmitoyltransferase deficiency (CPT) is a very rare autosomal recessive genetic disease created from the interaction of one gene from the mother and one gene from the father. Thus, the condition does not appear in the child unless the same defective gene for the same trait from each parent is inherited. If only one normal and one gene with the disease are passed on, the child will be a carrier of the disease but usually will not show symptoms. If both parents are carriers of the recessive disease, the child has a 25% chance of demonstrating positive symptoms of the disease, a 50% chance of being of carrier, and a 25% chance of receiving both normal genes from each parent.","og_url":"https:\/\/www.healthbenefitstimes.com\/glossary\/carnitine-palmitoyltransferase-deficiency-type-ii\/","og_site_name":"Glossary","article_published_time":"2021-05-26T04:40:37+00:00","author":"Glossary","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Glossary","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/carnitine-palmitoyltransferase-deficiency-type-ii\/","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/carnitine-palmitoyltransferase-deficiency-type-ii\/","name":"Carnitine palmitoyltransferase deficiency, type II - Definition of Carnitine palmitoyltransferase deficiency, type II","isPartOf":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website"},"datePublished":"2021-05-26T04:40:37+00:00","dateModified":"2021-05-26T04:40:37+00:00","author":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5"},"description":"Carnitine palmitoyltransferase deficiency (CPT) is a very rare autosomal recessive genetic disease created from the interaction of one gene from the mother and one gene from the father. Thus, the condition does not appear in the child unless the same defective gene for the same trait from each parent is inherited. If only one normal and one gene with the disease are passed on, the child will be a carrier of the disease but usually will not show symptoms. If both parents are carriers of the recessive disease, the child has a 25% chance of demonstrating positive symptoms of the disease, a 50% chance of being of carrier, and a 25% chance of receiving both normal genes from each parent.","breadcrumb":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/carnitine-palmitoyltransferase-deficiency-type-ii\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.healthbenefitstimes.com\/glossary\/carnitine-palmitoyltransferase-deficiency-type-ii\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/carnitine-palmitoyltransferase-deficiency-type-ii\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.healthbenefitstimes.com\/glossary\/"},{"@type":"ListItem","position":2,"name":"Carnitine palmitoyltransferase deficiency, type II"}]},{"@type":"WebSite","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/","name":"Glossary","description":"Difinitions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5","name":"Glossary","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/"}]}},"_links":{"self":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/108423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/comments?post=108423"}],"version-history":[{"count":1,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/108423\/revisions"}],"predecessor-version":[{"id":108424,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/108423\/revisions\/108424"}],"wp:attachment":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/media?parent=108423"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/categories?post=108423"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/tags?post=108423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}